Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO), has opened a microbial fermentation manufacturing facility in Billingham.
 
This new facility triples existing microbial production throughput by adding a new production line equipped with 2 X 4000 L fermenters, a primary separations suite and a modular purification suite.
 
To support further expansion, the facility is built with the flexibility to accommodate new projects to meet the emerging needs of Fujifilm Diosynth Biotechnologies’ partners, and to provide supply chain resilience.
 
This expansion was customized, in part, to support a large pharmaceutical partner with a highly specialized ophthalmic therapeutic for wet age-related macular degeneration (AMD).
 
“With the completion of this project, we are fulfilling our commitment with our partner, and supporting the commercialization of its ophthalmic therapeutic,” said Lars Petersen, president and CEO, Fujifilm Diosynth Biotechnologies. “This is a prime example of our partnership-based business model, a key element in our Partners for Life strategy, to help our customers bring their life-impacting medicines to patients.”